Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2008

View Archived Issues

New agents for treating neurological disorders disclosed in recent patent literature

Biolex signs agreement with OctoPlus to acquire 50% share of hepatitis C drug Locteron

Weight loss, increased urine output seen with lixivaptan in chronic heart failure patients

MolMed's partner Takara Bio starts phase I trial of TK for leukemia in Japan

Pipex Pharmaceuticals receives approval to initiate phase II oral flupirtine trial

Merck & Co. to evaluate use of once-daily raltegravir in HIV patients

Vical and AnGes sign letter of intent for pandemic influenza DNA vaccines in Japan

Comparative trial shows utility of biolimus-eluting stent with biodegradable polymer

Lux licenses from Isotechnika global rights to voclosporin in all ophthalmic indications

Hemispherx Biopharma seeking corporate partner for Ampligen

DSMB recommends continuation of BioMS Medical's phase II MINDSET-01 trial of dirucotide in MS

Recent patents describe new agents for diabetes and associated disorders

EMEA withdraws marketing authorization for Protopy in the European Union

Novel antiinfective agents disclosed in recent patents

Alnylam earns technology transfer milestone payment from Takeda

Phase I data on intravenous CP-4126 in solid tumors support phase II investigation

GSK-256066 inhibits allergen challenge responses in patients with asthma

FDA approves Akten ophthalmic gel 3.5%

FoldRx reports progress for Fx-1006A development program

Morria Biopharmaceuticals reports results from preclinical screening of antiinflammatory compounds

Novacta achieves first milestone in strategic translational award received from Wellcome Trust

R&D highlights from the UBS Global Life Sciences Conference in New York: Osiris Therapeutics

EpiCept receives marketing approval in Europe for Ceplene

Incyte reports safety and efficacy for INCB-018424 in proof-of-concept psoriasis study

Watson receives FDA approval for Rapaflo for benign prostatic hyperplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.